MétaCan
Menu
Back to cohort
Record W4409651336 · doi:10.1111/hae.70045

Global Comparative Antithrombin Field Study: Impact of Laboratory Assay Variability on the Assessment of Antithrombin Activity Measurement at Fitusiran Clinical Decision‐Making Points

2025· article· en· W4409651336 on OpenAlexafffund
Ekta Seth Chhabra, Ali Sadeghi‐Khomami, Mingjie Liu, Guy Young, Steven W. Pipe, Margareth C. Ozelo, Cecile Le Camus, Myew–Ling Toh, Marek Demissie, Flora Peyvandi

Bibliographic record

VenueHaemophilia · 2025
Typearticle
Languageen
FieldMedicine
TopicHemophilia Treatment and Research
Canadian institutionsPrecision BioLogic (Canada)
FundersBarts Health NHS TrustFiona Stanley HospitalKaohsiung Medical University Chung-Ho Memorial HospitalTri-Service General HospitalHospices Civils de LyonCentre Hospitalier Universitaire de NantesChristian Medical College, VelloreRheinische Friedrich-Wilhelms-Universität BonnNSW Health PathologyUniversity of Chicago MedicineHumanitas Research HospitalAlfaisal UniversityCentre hospitalier régional universitaire de LilleKing Faisal Specialist Hospital and Research CentreGeorgetown UniversityVanderbilt UniversityARUP LaboratoriesMcMaster UniversityUniversity Hospital Southampton NHS Foundation TrustKaohsiung Medical UniversitySanofi
KeywordsMedicineAntithrombinInternal medicine

Abstract

fetched live from OpenAlex

INTRODUCTION: Fitusiran is a subcutaneous, investigational small interfering RNA therapeutic that lowers antithrombin (AT) to increase thrombin generation and rebalance haemostasis in people with haemophilia A or B with or without inhibitors. AIM: To evaluate and compare the performance of commercially available in vitro diagnostic (IVD) AT activity assays. METHODS: Field study sample kits with plasma AT activity levels (100, 36, 14 and 9 IU/dL or % of normal) were created and distributed to global haemostasis laboratories. Values were assigned based on Siemens INNOVANCE AT activity assay using BCS-XP analyser. Reliability (relative accuracy estimate), intra- and inter-laboratory variability of IVDs in measuring AT activity in plasma samples using various commercially available AT assays was assessed. RESULTS: At normal AT activity level (i.e., 100%), all AT assays reliably measured AT activity with acceptable recovery. Accurate results were observed for all samples across sites using Siemens INNOVANCE AT assay. Increased variability was observed for all other assays at low AT levels. Siemens Berichrom and Stago STA-Stachrom assays accurately measured 100% and 36% AT activity; however, lab-to-lab variability was observed for ≤15% AT activity (CV >20%). All laboratories for the Stago STA-Stachrom assay failed to measure 9% AT activity. The HemosIL assay significantly underestimated AT activity levels ≤36%. There were no reported values for the 14% and 9% AT samples. CONCLUSIONS: Siemens INNOVANCE AT assay can reliably measure AT activity at clinical decision points of 15-35% of normal and is most suitable for clinical management of patients taking fitusiran.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.047
metaresearch head score (Gemma)0.054
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.047
Threshold uncertainty score0.246

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0470.054
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.119
GPT teacher head0.492
Teacher spread0.373 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueHaemophiliaSame topicHemophilia Treatment and ResearchFrench-language works237,207